Pacira | PCRX - Umsatzkosten





Umsatzkosten Veränderung Datum
Assertio Holdings USD 8.89M 2.29M 2024-06
Astellas Pharma JPY 129.43B 19.7B 2026-03
Bristol-Myers Squibb USD 3.86B 1.07B 2026-03
Cara Therapeutics USD 0 0 2025-03
Coherus Biosciences USD 4.04M 324K 2025-12
Heron Therapeutics USD 11.12M 795K 2025-12
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
J&J USD 8.07B 103M 2026-03
Ligand Pharmaceuticals USD 11.9M 733K 2025-09
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Novo Nordisk DKK 15.15B 2.3B 2025-12
Omeros USD 33.16M 18.52M 2024-06
Pacira USD 54.62M 6.02M 2025-12
Perrigo USD 747.4M 81.2M 2025-12
Pfizer USD 6.29B 2.12B 2025-12
Supernus Pharmaceuticals USD 47.53M 4.24M 2025-12
Teva Pharmaceutical Industries USD 2.01B 46M 2026-03
Xeris Pharmaceuticals USD 13.66M 49K 2025-12
Xoma 116K 112.7K 2024-06
Zoetis USD 743M 60M 2025-12